IQVIA Holdings Inc (IQV)vsVeracyte Inc (VCYT)
IQV
IQVIA Holdings Inc
$165.64
-0.27%
HEALTHCARE · Cap: $28.11B
VCYT
Veracyte Inc
$32.79
-0.46%
HEALTHCARE · Cap: $2.62B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 3054% more annual revenue ($16.31B vs $517.14M). VCYT leads profitability with a 12.8% profit margin vs 8.3%. IQV trades at a lower P/E of 21.2x. IQV earns a higher WallStSmart Score of 72/100 (B).
IQV
Strong Buy72
out of 100
Grade: B
VCYT
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.1%
Fair Value
$348.46
Current Price
$165.64
$182.82 discount
Margin of Safety
+3.9%
Fair Value
$37.44
Current Price
$32.79
$4.65 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Earnings expanding 23.6% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
18.5% revenue growth
Areas to Watch
Distress zone — elevated risk
ROE of 5.3% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : VCYT
The strongest argument for VCYT centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 18.5% demonstrates continued momentum.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Bear Case : VCYT
The primary concerns for VCYT are Return on Equity, P/E Ratio. A P/E of 41.2x leaves little room for execution misses.
Key Dynamics to Monitor
IQV profiles as a value stock while VCYT is a growth play — different risk/reward profiles.
VCYT carries more volatility with a beta of 1.96 — expect wider price swings.
VCYT is growing revenue faster at 18.5% — sustainability is the question.
IQV generates stronger free cash flow (561M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (72/100 vs 59/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Veracyte Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?